You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2014
|
| DOI | 10.3389/fphar.2014.00010 |
| Pubmed ID | |
| Authors |
Raquel Levin, Fernanda F. Peres, Valéria Almeida, Mariana B. Calzavara, Antonio W. Zuardi, Jaime E. C. Hallak, José Alexandre S. Crippa, Vanessa C. Abílio |
| Abstract |
Clinical and neurobiological findings suggest that the cannabinoids and the endocannabinoid system may be implicated in the pathophysiology and treatment of schizophrenia. We described that the spontaneously hypertensive rats (SHR) strain presents a schizophrenia behavioral phenotype that is specifically attenuated by antipsychotic drugs, and potentiated by proschizophrenia manipulations. Based on these findings, we have suggested this strain as an animal model of schizophrenia. The aim of this study was to evaluate the effects of cannabinoid drugs on the deficit of prepulse inhibition (PPI) of startle, the main paradigm used to study sensorimotor gating impairment related to schizophrenia, presented by the SHR strain. The following drugs were used: (1) WIN55212,2 (cannabinoid agonist), (2) rimonabant (CB1 antagonist), (3) AM404 (anandamide uptake inhibitor), and (4) cannabidiol (CBD; indirect CB1/CB2 receptor antagonist, among other effects). Wistar rats (WRs) and SHRs were treated with vehicle (VEH) or different doses of WIN55212 (0.3, 1, or 3 mg/kg), rimonabant (0.75, 1.5, or 3 mg/kg), AM404 (1, 5, or 10 mg/kg), or CBD (15, 30, or 60 mg/kg). VEH-treated SHRs showed a decreased PPI when compared to WRs. This PPI deficit was reversed by 1 mg/kg WIN and 30 mg/kg CBD. Conversely, 0.75 mg/kg rimonabant decreased PPI in SHR strain, whereas AM404 did not modify it. Our results reinforce the role of the endocannabinoid system in the sensorimotor gating impairment related to schizophrenia, and point to cannabinoid drugs as potential therapeutic strategies. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 20% |
| Switzerland | 1 | 10% |
| Finland | 1 | 10% |
| Brazil | 1 | 10% |
| Unknown | 5 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 60% |
| Scientists | 2 | 20% |
| Practitioners (doctors, other healthcare professionals) | 2 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Netherlands | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 111 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 23 | 20% |
| Student > Ph. D. Student | 20 | 17% |
| Student > Master | 15 | 13% |
| Researcher | 7 | 6% |
| Professor | 7 | 6% |
| Other | 21 | 18% |
| Unknown | 22 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 28 | 24% |
| Agricultural and Biological Sciences | 17 | 15% |
| Psychology | 12 | 10% |
| Medicine and Dentistry | 11 | 10% |
| Biochemistry, Genetics and Molecular Biology | 8 | 7% |
| Other | 12 | 10% |
| Unknown | 27 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2020.
All research outputs
#4,781,876
of 25,632,496 outputs
Outputs from Frontiers in Pharmacology
#2,298
of 19,993 outputs
Outputs of similar age
#52,117
of 320,610 outputs
Outputs of similar age from Frontiers in Pharmacology
#7
of 40 outputs
Altmetric has tracked 25,632,496 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,993 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,610 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.